Routine blood test predicts how long cancer patients will survive - Medical News Today

Medical News Today

...Previous models for predicting prognosis used subjective conditions such as dyspnoea and delirium which may be scored differently by clinicians. These conditions were assessed once (at the start of treatment, for example), limiting the use of the models to that time point.
The current Six Adaptable Prognostic (SAP) models use three laboratory measurements (albumin, neutrophil, lactate dehydrogenase) which are routinely monitored in daily clinical practice with a blood test. The models can be used at any time point after the initiation of treatment - an important feature since a patient's condition can change. The six models were developed in approximately 5,000 cancer patients receiving chemotherapy at Kyoto University Hospital in Japan....

References
1. Abstract 484O_PR - ‘Validation of the set of six adaptable prognosis prediction (SAP) models for cancer patients in palliative care settings: A sub analysis of the Japan-prognostic assessment tools validation (J-ProVal) study’ will be presented by Dr Yu Uneno during the Proferred Paper session ‘Supportive and palliative care’: on Sunday, 18 December, 09:00 - 10:45 (SGT).
2. Kirk P, et al. What do patients receiving palliative care for cancer and their families want to be told? A Canadian and Australian qualitative study. BMJ. 2004;328:1343. doi: 10.1136/bmj.38103.423576.55
3. Kutner JS, et al. Information needs in terminal illness. Soc Sci Med. 1999;48:1341–1352.
4. Baba M, et al. Survival prediction for advanced cancer patients in the real world: A comparison of the Palliative Prognostic Score, Delirium-Palliative Prognostic Score, Palliative Prognostic Index and modified Prognosis in Palliative Care Study predictor model. Eur J Cancer. 2015;51:1618-1629. doi: 10.1016/j.ejca.2015.04.025.
5. Steinhauser KE, et al. Preparing for the end of life: preferences of patients, families, physicians, and other care providers. J Pain Symptom Manage. 2001;22:727-737.
Source: European Society for Medical Oncology (ESMO)